StemCell Therapy

Winter nights make joint pain worse and a snug comfortable bed with extra blankets will allow your pet to relax while theyre lying down and recuperating. Photo submitted.

While the cold weather may bring many positives such as TV series marathons in bed and an excuse to have just one more mug of hot chocolate, it unfortunately can also bring with it a lot of discomfort to our fur babies, said Hills Pet Nutrition.

According to Dr Guy Fyvie, Hills Pet Nutritions veterinary advisor, winter can exacerbate existing ailments, such as arthritis and, while we may be able to verbalise our pain, unfortunately our pets cant.

When it comes to cats its especially difficult for pet parents to acknowledge their pain as theyre absolute masters of disguise a survival instinct. Caused by the wear and tear of cartilage and bone of the joints, osteo-arthritis, if not managed properly can become extremely painful and debilitating.

He explained that pets are more likely to develop arthritis as they age, but at times it can occur in younger pets as a secondary ailment.

This could be due to an inherited disease such as hip or elbow dysplasia, or trauma to cartilage and ligaments.

He said according to the World Small Animal Veterinary Association (WSAVA) arthritis in pets is not a single type of problem and presents differently in the growing, versus the middle-aged, versus the older cat or dog.

Therefore, arthritis presenting at the different life stages requires a unique approach for optimal care. For example, in a growing dog surgical intervention may be the first line of treatment in an effort to limit the disease progression and the likelihood of pain in the future, whereas an older cat, for example, may require pain management and dietary changes.

We know arthritic cats hide their discomfort very well, so signs pet parents should look out for are sleeping all day, which contrary to popular belief isnt normal. Its called slowing down, and is almost always pain related. Also look out for a scruffier coat, especially around the tail area as they struggle to groom. Other signs are battling or being reluctant to jump, and having problems negotiating a high-sided cat litter box.

0828473906

0828473906

0828473906

Its not all doom and gloom, however. Dr. Fyvie said the good news is that there are plenty of things pet parents can do to reduce arthritis pain and improve their pets quality of life:

Weight management Carrying a little extra weight can become a significant load on your pets joints and can increase the inflammation, pain, and stress in an already arthritic pet. Maintaining optimum weight should be a priority. If your pets weight is a concern, make an appointment with your vet. Your vet will objectively assess their weight, recommend nutritional and lifestyle changes if necessary, and prescribe pain relief or anti-inflammatory medication, as required.

Regular exercise Its harder for all of us to get up and moving in winter, its just so cold. However, its important to maintain regular gentle exercise with our pets to keep their joints healthy and moving. A brisk walk with your dog when the winter sun is high, or a play session with your cat and an empty toilet roll will do wonders for everyones physical and mental well-being and is critical in the management of arthritis.

Comfortable bedding Make sure your pet has a warm and sheltered area that is out of the cold, wet and wind. Winter nights make joint pain worse and a snug comfortable bed with extra blankets will allow your pets to relax while theyre lying down and recuperating. Just make sure your pets bed isnt on a high level or is difficult to get in and out of, as this can put added pressure on their joints.

Avoid stairs For really arthritic pets, minimising access to stairs, where possible, can reduce unnecessary trauma. If stairs are unavoidable you may have to carry small pets up and down or use ramps around the house, if space allows. If jumping in and out of the car proves problematic for your larger dog, then consider a portable ramp to make this transition easier. For cats specifically, lower their food, water bowls and litter trays for easy access or, if this isnt possible, ensure there is a halfway jump to get up to them.

Anti-inflammatory medication Be sure to consult your vet for the correct pet medication cats especially do not tolerate human medicines, which can be fatal.

Nutrition The food your pet eats plays an important role in their overall health and well-being. For accurate diagnosis and treatment options, always consult your veterinarian and ask them to recommend the best food for your pets arthritis and joint health.

Read more:
Why our pets may be feeling the cold more than we think - Krugersdorp News

HealthA condition which causes deformity of the hand leading to impairment and disability can now be successfully treated by using drugs developed in recent years for the treatment of different forms of arthritis.

Saturday, 11th July 2020, 7:30 am

The deformity can impair hand movement to the extent it limits daily activities severely, including self-care and employment, reducing health-related quality of life.

Sign up to our public interest bulletins - get the latest news on the Coronavirus

Sign up to our public interest bulletins - get the latest news on the Coronavirus

There are no approved treatments for the early stages of the disease and a high recurrence in late-stage disease when therapies including surgery and injection therapy which work for only a limited length of time.

Across the UK, the prevalence of the disease is approximately 20 per cent.

In Scotland the prevalence is much higher 40 per cent of the population - and in Scandinavian countries, it affects around 30 per cent of men over 60. This is because the disease is genetic; Scots are affected more than other parts of the UK because more people carry Celtic or Irish genes.

The drugs are: Cytokine inhibitors which has been used for treating rheumatoid and other forms of arthritis for around 15 years and JAK inhibitors which became available around five years ago, and is also used for the treatment of inflammatory arthritis.

Mr Millar said: Our work using patient samples from Dupuytrens Disease has discovered a key role for these drugs.

We were able to reverse these fibrotic changes in human cells. Until now, there has been nothing out there for these patients.

The two arthritis drugs are licensed for use in the treatment of that disease but under drug regulations, they must undergo further testing for use in the treatment of a different disease.

Mr Millar and his team have submitted a patent for the discovery of the new use of the drugs. They have also been awarded a grant from the Medical Research Council to conduct experimental therapeutic trials which he anticipates could start in a years time.

Retired teacher Andrew Tod from Edinburgh has lived with Dupuytrens Disease for the past 40 years and has undergone two operations on each hand.

He said: Anything that publicises this condition is going down the right lines.

I developed it without knowing what it was.

I just assumed like a pain in the ankle or something that it would just disappear and then it gradually got a little bit worse and a little bit worse in both hands.

So, that when I was working they would give me the nickname of the claw.

Basically it got worse and I did nothing about it - then I had two operations on one hand and two on the other.

To be honest it was really too late by that point.

I remember one of the surgeons asking me if Id ever heard of something called the bell curve?

It said my hands were off the radar for this measurement - so in other words I had neglected them all these years.

Theyre no better now but theyre no worse.

Ive got one finger on the left hand that works OK and one thats fine on the right, so typing is not a problem - I only use two fingers anyway. I can type and I can brush my teeth and perform the health measures.

My father had muscular dystrophy and I learnt from him that if you have a disability you have to adapt, it may take longer for you to do things but you just adapt.

Ive had no pain of any kind with it at all - all Ive had is inconvenience.

Im delighted theyve found drugs that could be effective and if someone gets the symptoms in their 30s and that means they can then be prepared for life as a professional pianist then splendid.

The condition is also known as the Curse of the MacCrimmons who were the 16th century pipers for the chieftains of Clan MacLeod on the Isle of Skye.

Folklore has it a curse was put on them for revealing piping secrets and it was foretold they would cease to be the official pipers to the MacLeods and would leave the Isle of Skye forever.

So, it came to pass. The fingers of the MacCrimmon men bent so far into their palms they became unable to play the bagpipes any more. Any piper who suffers from Dupuytrens Contracture as it is also known will tell you he has been affected by the Curse of the MacCrimmons.

A message from the Editor:

Thank you for reading this story on our website. While I have your attention, I also have an important request to make of you.

The dramatic events of 2020 are having a major impact on many of our advertisers - and consequently the revenue we receive. We are now more reliant than ever on you taking out a digital subscription to support our journalism.

By supporting us, we are able to support you in providing trusted, fact-checked content for this website.

Read the original:
Arthritis drugs can cure hand deformity - The Scotsman

While the cold weather may bring many positives such as TV series marathons in bed and an excuse to have just one more mug of hot chocolate, what it can also unfortunately bring with it is a lot of discomfort to our fur babies.

Winter can exacerbate existing ailments, such as arthritis and, while we may be able to verbalise our pain, unfortunately our pets cant.

When it comes to cats its especially difficult for pet parents to acknowledge their pain as theyre absolute masters of disguise a survival instinct.

Caused by the wear and tear of cartilage and bone of the joints, osteo-arthritis, if not managed properly can become extremely painful and debilitating, said Dr Guy Fyvie, Hills Pet Nutritions veterinary advisor.

He explains that pets are more likely to develop arthritis as they age, but at times it can occur in younger pets as a secondary ailment.

This could be due to an inherited disease such as hip or elbow dysplasia, or trauma to cartilage and ligaments.

According to the World Small Animal Veterinary Association (WSAVA) arthritis in pets is not a single type of problem and presents differently in the growing, versus the middle-aged, versus the older cat or dog.

Therefore, arthritis presenting at the different life stages requires a unique approach for optimal care. For example, in a growing dog surgical intervention may be the first line of treatment in an effort to limit the disease progression and the likelihood of pain in the future, whereas an older cat, for example, may require pain management and dietary changes.

We know arthritic cats hide their discomfort very well, so signs pet parents should look out for are:

1. Sleeping all day, contrary to popular belief this isnt normal. Its called slowing down, and is almost always pain related.

2. Look out for a scruffier coat especially around the tail area as they struggle to groom

3. Battling or are reluctant to jump.

4. Have problems negotiating a high-sided cat litter box.

Its not all doom and gloom, however. Fyvie says the good news is that there are plenty of things pet parents can do to reduce arthritis pain and improve their pets quality of life.

Weight management Carrying a little extra weight can become a significant load on your pets joints and can increase the inflammation, pain, and stress in an already arthritic pet.

Maintaining optimum weight should be a priority. If your pets weight is a concern, make an appointment with your vet.

Your vet will objectively assess their weight, recommend nutritional and lifestyle changes if necessary, and prescribe pain relief or anti-inflammatory medication, as required.

A food like Hills Prescription Diet Metabolic + Mobility can also help to support pets joints while assisting them in losing those extra kilos and maintaining a healthy weight.

Regular exercise Its harder for all of us to get up and moving in winter, its just so cold.

However, its important to maintain regular gentle exercise with our pets to keep their joints healthy and moving.

A brisk walk with your dog when the winter sun is high, or a play session with your cat and an empty toilet roll will do wonders for everyones physical and mental wellbeing and is critical in the management of arthritis.

Comfortable bedding Make sure your pet has a warm and sheltered area that is out of the cold, wet and wind.

Winter nights make joint pain worse and a snug comfortable bed with extra blankets will allow your pet to relax while theyre lying down and recuperating.

Just make sure your pets bed isnt on a high level or is difficult to get in and out of, as this can put added pressure on their joints.

Avoid stairs For really arthritic pets, minimising access to stairs, where possible, can reduce unnecessary trauma.

If stairs are unavoidable you may have to carry small pets up and down or use ramps around the house, if space allows.

If jumping in and out of the car proves problematic for your larger dog, then consider a portable ramp to make this transition easier.

For cats specifically, lower their food, water bowls and litter trays for easy access or, if this isnt possible, ensure there is a halfway jump to get up to them.

Anti-inflammatory medication Be sure to consult your vet forthe correct pet medication cats especially do not tolerate human medicines, which can be fatal.

Nutrition The food your pet eats plays an important role in their overall health and well-being.

Hills Prescription Diet j/d and mobility range of foods for dogs and cats are made with high levels of specific Omega-3 fatty acids, Glucosamine and Chondroitin, and is the only food clinically proven to improve mobility in as little as 21 days.

For accurate diagnosis and treatment options, always consult your veterinarian and ask them to recommend the best food for your pets arthritis and joint health.

Ideally, but unfortunately not in all cases, the management of arthritis should be a gentle one, involving a combination of the above approaches to optimise your pets comfort. The most important thing to remember though is to keep a close eye on your pet and if you notice any changes in their behaviour, make an appointment with your vet. Prevention is always better than cure, said Fyvie.

Have a story?

Contact the newsroom by emailing:Thelma Koorts (editor)[emailprotected]

orStacy Slatter (news editor)[emailprotected]

or Min Fourie(journalist)[emailprotected]

Remember to visit theBrakpan Heraldon the following social media platforms:

Follow us:

Go here to see the original:
Why our pets may be feeling the cold more than we think - Brakpan Herald

Global Rheumatoid Arthritis Treatment Market presents insights into the present and upcoming industry trends, enabling the readers to identify the products and services, hence driving the enlargement and effectiveness. The research report provides a comprehensive breakdown of all the major factors impacting the market on a global and regional scale, including drivers, constraints, intimidation, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

Get more information on Global Rheumatoid Arthritis Treatment Market Research Report by requesting FREE Sample Copy @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#request_sample

Major Players:

Johnson & JohnsonAmgen Inc.Sobi Inc.UCB S.A.Eli Lilly & CompanySanofi SAAbbVie Inc.Pfizer Inc.Bristol-Myers Squibb CompanyF. Hoffman-La Roche AG

Global Rheumatoid Arthritis Treatment Market research reports enlargement rates and the market value based on market dynamics, growth factors. Complete knowledge is based on the newest innovation in business, opportunities, and trends. In addition to SWOT examination by key suppliers, the report contains an all-inclusive market analysis and major players landscape.

The regional segmentation covers:

Segmentation by Type:

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)CorticosteroidsDisease-modifying anti-rheumatic drugs (DMARDs)

Segmentation by Application:

HospitalRetail PharmaciesDrugstores

Do Inquiry Before Purchasing Report Here and Ask For Discount @: https://www.globalmarketers.biz/discount_inquiry/discount/146290

Report Objectives

Enquire Before Buying : https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#inquiry_before_buying

Table of Content:

The Global Rheumatoid Arthritis Treatment Market

Chapter 1: Rheumatoid Arthritis Treatment Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Rheumatoid Arthritis Treatment Market Competition by Manufacturers

Chapter 3: Rheumatoid Arthritis Treatment Production by Regions

Chapter 4: Production, By Types, Market share by Types

Chapter 5: Consumption, By Applications

Chapter 6: Comprehensive profiling and analysis of Manufacturers

Chapter 7: Manufacturing cost analysis

Chapter 8: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 9: Marketing Strategy Analysis, Distributors/Traders

Chapter 10: Rheumatoid Arthritis Treatment Market Effect Factors Analysis

Chapter 11: Rheumatoid Arthritis Treatment Market Forecast

Chapter 12: Conclusion of Rheumatoid Arthritis Treatment Market

The Report has Tables and Figures Browse The Report Description and TOC @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#table_of_contents

See original here:
Global Rheumatoid Arthritis Treatment Market Analysis and Forecast 2027- including drivers, constraints, intimidation, challenges, opportunities, and...

The Canine Arthritis Treatment Market research report added by Market Study Report, LLC, provides a succinct analysis on the recent market trends. In addition, the report offers a thorough abstract on the statistics, market estimates and revenue forecasts, which further highlights its position in the industry, in tandem with the growth strategies adopted by leading industry players.

The Canine Arthritis Treatment market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Canine Arthritis Treatment market and the trends that will prevail in this industry.

Request Sample Report @https://www.mrrse.com/sample/17398?source=atm

What pointers are covered in the Canine Arthritis Treatment market research study?

The Canine Arthritis Treatment market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Canine Arthritis Treatment market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Canine Arthritis Treatment market report Elucidated with regards to the competitive landscape of the industry:

The second dominant market in canine arthritis treatment is Germany owing to the rise in prevalence of chronic diseases in animals, particularly dogs. It has been found that with growing age of pets, the prevalence of diseases such as allergies, lower appetite, reduced energy, arthritis, lameness, dysplasia and behavioural anxieties increases, especially in dogs and cats. This growth in terms of pet adoption in European countries and increasing number of pets suffering from arthritis is likely to boost the growth of canine arthritis treatment in Europe. This has been driving the demand for innovative therapies and drugs in Canine Arthritis Treatment, such as stem cell Canine Arthritis Treatment and arthritis drugs NSAIDs and opioids. Canine arthritis treatment/drugs in Germany have taken initiatives to incentivize innovation in the field of veterinary treatment in order to address the urgent need of better veterinary care and to combat rapid growing prevalence of animal diseases. Additionally, increasing expenditure on vet care in high economic European countries such as Germany, France and the U.K. also boosts the growth of the market for canine arthritis treatment. As per the American Pet Products Association, about US$ 6.1 Bn was spent on vet care in 2017 in Europe.

Increasing pet adoption in China and India is expected to drive the growth of the canine arthritis treatment market in Asia-Pacific. In Japan and the Middle East and Africa, the population of dogs is decreasing due to poor vet care facilities, which is expected to hamper the growth of canine arthritis treatment market to some extent.

Request For Discount On This Report @ https://www.mrrse.com/checkdiscount/17398?source=atm

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Canine Arthritis Treatment market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Canine Arthritis Treatment market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Canine Arthritis Treatment market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

Buy This Report @ https://www.mrrse.com/checkout/17398?source=atm

Some of the Major Highlights of TOC covers:

See original here:
Research Report and Overview on Canine Arthritis Treatment Market, 2019-2026 - Cole of Duty

Rheumatoid Arthritis Diagnostic Device Market (2018) Report Provides an in-depth summary of Rheumatoid Arthritis Diagnostic Device Market Status as well as Product Specification, Technology Development, and Key Manufacturers. The Report Gives Detail Analysis on Market concern Like Rheumatoid Arthritis Diagnostic Device Market share, CAGR Status, Market demand and up to date Market Trends with key Market segments.

The latest report about the Rheumatoid Arthritis Diagnostic Device market provides a detailed evaluation of the business vertical in question, alongside a brief overview of the industry segments. An exceptionally workable estimation of the present industry scenario has been delivered in the study, and the Rheumatoid Arthritis Diagnostic Device market size with regards to the revenue and volume have also been mentioned. In general, the research report is a compilation of key data with regards to the competitive landscape of this vertical and the multiple regions where the business has successfully established its position.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2609409&source=atm

Scope of The Rheumatoid Arthritis Diagnostic Device Market Report:

This research report for Rheumatoid Arthritis Diagnostic Device Market explores different topics such as product scope, product market by end users or application, product market by region, the market size for the specific product Type, sales and revenue by region forecast the Market size for various segments. The Report provides detailed information regarding the Major factors (drivers, restraints, opportunities, and challenges) influencing the growth of the Rheumatoid Arthritis Diagnostic Device market. The Rheumatoid Arthritis Diagnostic Device Market Report analyzes opportunities in the overall Rheumatoid Arthritis Diagnostic Device market for stakeholders by identifying the high-growth segments.

The report firstly introduced the Rheumatoid Arthritis Diagnostic Device basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The major players profiled in this report include:Abbott LaboratoriesDanaher Corp.F. Hoffmann-La Roche Ltd.Siemens Healthineers AGThermo Fisher Scientific Inc.

The end users/applications and product categories analysis:On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-AnalyzersConsumables

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Rheumatoid Arthritis Diagnostic Device for each application, including-HospitalResearch instituteClinic

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2609409&source=atm

A detailed overview of the geographical and competitive sphere of the Rheumatoid Arthritis Diagnostic Device market:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2609409&licType=S&source=atm

Table of Content of The Report

Chapter 1- Rheumatoid Arthritis Diagnostic Device Industry Overview:

1.1 Definition of Rheumatoid Arthritis Diagnostic Device

1.2 Brief Introduction of Major Classifications

1.3 Brief Introduction of Major Applications

1.4 Brief Introduction of Major Regions

Chapter 2- Production Market Analysis:

2.1 Global Production Market Analysis

2.1.1 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis

2.1.2 Major Manufacturers Performance and Market Share

2.2 Regional Production Market Analysis

Chapter 3- Sales Market Analysis:

3.1 Global Sales Market Analysis

3.2 Regional Sales Market Analysis

Chapter 4- Consumption Market Analysis:

4.1 Global Consumption Market Analysis

4.2 Regional Consumption Market Analysis

Chapter 5- Production, Sales and Consumption Market Comparison Analysis

Chapter 6- Major Manufacturers Production and Sales Market Comparison Analysis

Chapter 7- Major Classification Analysis

Chapter 8- Major Application Analysis

Chapter 9- Industry Chain Analysis:

9.1 Up Stream Industries Analysis

9.2 Manufacturing Analysis

Chapter 10- Global and Regional Market Forecast:

10.1 Production Market Forecast

10.2 Sales Market Forecast

10.3 Consumption Market Forecast

Chapter 11- Major Manufacturers Analysis:

11.1.1 Company Introduction

11.1.2 Product Specification and Major Types Analysis

11.1.3 Production Market Performance

11.1.4 Sales Market Performance

11.1.5 Contact Information

11.2.1 Company Introduction

11.2.2 Product Specification and Major Types Analysis

11.2.3 Production Market Performance

11.2.4 Sales Market Performance

11.2.5 Contact Information

Chapter 12- New Project Investment Feasibility Analysis:

12.1 New Project SWOT Analysis

12.2 New Project Investment Feasibility Analysis

Continued

Go here to read the rest:
Rheumatoid Arthritis Diagnostic Device Market Expected to Witness an Imperishable Growth over 2025 - Jewish Life News

Drugs for Rheumatoid Arthritis Market has witnessed continuous growth within the past few years and is projected to grow even more throughout the forecast period (2020 2027). The analysis presents a whole assessment of the market and contains Future trends, Current Growth Factors, attentive opinions, facts, historical information, and statistically supported and trade valid market information.

The report, titled Global Drugs for Rheumatoid Arthritis Market defines and briefs readers about its products, applications, and specifications. The research lists key companies operating in the global market and also highlights the key changing trends adopted by the companies to maintain their dominance. By using SWOT analysis and Porters five force analysis tools, the strengths, weaknesses, opportunities, and threats of key companies are all mentioned in the report. All leading players in this global market are profiled with details such as product types, business overview, sales, manufacturing base, competitors, applications, and specifications.

You Can Request A Demo Version of Report Before Buying (Higher Preference For Corporate Email ID User): https://www.worldwidemarketreports.com/sample/201374

AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG, Regeneron Pharmaceuticals Inc., Pfizer Inc., Johnson & Johnsons Services Inc, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Amgen Inc. of the major organizations dominating the global market.(*Note: Other Players Can be Added per Request)

1. Industry outlookThis is where youll find the current state of the Drugs for Rheumatoid Arthritis industry overall and where its headed. Relevant industry metrics like size, trends, life cycle, and projected growth included here. This report comes prepared with the data to back up your business idea. On a regional basis, the Global Drugs for Rheumatoid Arthritis market has been segmented into Asia-Pacific, North America, Europe, Latin America, and the Middle East and Africa.

2. Target marketThis target market section of study includes the following:

User persona and characteristics: It includes demographics such as age, income, and location. It lets you know what their interests and buying habits are, as well as explain the best position to meet their needs.

Market size: How big is the potential Drugs for Rheumatoid Arthritis market for your business? It brings to light the consumption in the Drugs for Rheumatoid Arthritis industry by the type and application.

3. Competitive analysisDiscover your competitors. The report lets you know what youre up against, but it also lets you spot the competitions weaknesses. Are there customers that are underserved? What can you offer that similar businesses arent offering? The competitive analysis contains the following components:

Direct competitors: What other companies are offering similar products and services? Which companies are your true competitors?

Competitor strengths and weaknesses: What is your competition good at? Where do they fall behind? Get insights to spot opportunities to excel where others are falling short.

Barriers to entry: What are the potential pitfalls of entering the Drugs for Rheumatoid Arthritis market? Whats the cost of entry? Is it prohibitively high, or easy to enter?

The window of opportunity:Does your entry into the Drugs for Rheumatoid Arthritis industry rely on time-sensitive technology? Do you need to enter early to take advantage of an emerging market?

4. ProjectionsLikewise, We offered thoughtful, not hockey-stick forecasting.

Market share:We have given the consumption behavior of users. When you know how much can your future customers spend, then only youll understand how much of the Drugs for Rheumatoid Arthritis industry you have a chance to grab, and here we came up with real stats and numbers.

Impact Analysis of COVID-19:The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into account the political, economic, social, and technological parameters.

Finally, It is one report that hasnt shied away from taking a critical look at the current status and future outlook for the consumption/sales of these products, by the end users and applications. Not forgetting the market share control and growth rate of the Drugs for Rheumatoid Arthritis Industry, per application. Most noteworthy, this market analysis will help you find market blind spots.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Contact Us:

Mr. ShahWorldwide Market ReportsSeattle, WA 98154,U.S.Email: [emailprotected]

Go here to read the rest:
Drugs for Rheumatoid Arthritis Market Evolution of Key Players That Will Change Industry AbbVie Inc., Boehringer Ingelheim GmbH, Novartis AG - Daily...

Rheumatoid factor (RF) isotypes and anticitrullinated protein antibodies (ACPA) are strongly associated with future cardiovascular (CV) events, including acute coronary syndrome (ACS) and stroke, in patients with rheumatoid arthritis (RA), according to study results published in Arthritis and Rheumatology.

The study cohort included patients from the Swedish Epidemiological Investigation of RA who received a diagnosis of RA between 1996 and 2009 (N=2814). Using these cases, researchers centrally typed baseline serologic data based on the anticyclic citrullinated peptide test (anti-CCP2), 20 ACPA subspecificities, and RF isotypes. Patients were followed over a median 13-year follow-up period through the Swedish national patient register and cause of death register until the first event of ACS, stroke, CV-related mortality, or major adverse CV event (MACE). The association between each serologic marker and CV outcome was examined and adjustments were made for baseline Disease Activity Score in 28 joints (DAS28), smoking, and income level.

During the follow-up period, a total of 375 first ACS, stroke, and CV death events occurred. There was an association between anti-CCP2 positivity and risk for incident ACS (hazard ratio [HR], 1.46; 95% CI, 1.03-2.06; P =.035), stroke (HR, 1.47; 95% CI, 1.03-2.10; P =.034), and MACE (HR, 1.34; 95% CI, 1.06-1.70; P =.014). A similar nonsignificant association was found between anti-CCP2 positivity and CV death (HR, 1.48; 95% CI, 0.94-2.31; P =.087).

Immunoglobulin M (IgM) RF was associated with stroke (HR, 1.42; 95% CI, 1.01-2.01; P =.045) and MACE (HR, 1.40; 95% CI, 1.11-1.76; P =.0045). The researchers also observed a significant association between IgA RF and an increased risk for CV mortality (HR, 1.88; 95% CI, 1.22-2.88; P =.0038). After adjustment for smoking, income, and DAS28, IgA RF remained associated with CV mortality (HR, 1.61; 95% CI, 1.05-2.48). In analyses stratified by smoking status, IgA and IgG RF were associated with CV mortality and IgG and IgM RF were associated with MACE in patients who had never smoked.

Strong associations were found between all-cause mortality and anti-CCP2 positivity, anti-CCP2 level, autoantibody load, the majority of the ACPA subspecificities, and each RF isotype.

A limitation of this study was the lack of adjustment for lipid profile, family history of cardiovascular disease, physical activity, and comorbid conditions.

The researchers suggested that with regard to the risk for CV events, patients with high anti-CPP2 levels or presence of IgA or IgG RF at diagnosis are at higher risk and might benefit from closer monitoring from a cardio preventative perspective.

Disclosure: Several study authors declared affiliations with the pharmaceutical industry. Please see the original reference for a full list of authors disclosures.

Reference

Westerlind H, Rnnelid J, Hansson M, et al. Anti-citrullinated protein antibody specificities, rheumatoid factor isotypes and incident cardiovascular events in patients with rheumatoid arthritis [published online May 31, 2020]. Arthritis Rheumatol. doi:10.1002/art.41381

Read more here:
Rheumatoid Factor Isotypes, ACPAs Show Strong Associations With Future Cardiovascular Events in RA - Rheumatology Advisor

Pain and fatigue in patients with psoriatic arthritis (PsA) receiving tumor necrosis factor inhibitors (TNFis) significantly reduce health-related quality of life (HRQoL), physical function, and work productivity, according to study results published in Rheumatic and Musculoskeletal Diseases.

In this retrospective analysis of global data, researchers evaluated the incidence and severity of pain and fatigue in patients with PsA receiving TNFis, and assessed the association between pain and fatigue severity and HRQoL and work productivity.

A total of 3782 patients with PsA undergoing TNFi treatment participated in the study. Characteristics including patient demographics and comorbidities were collected by questionnaires completed by both patients and their physicians; patient-reported forms included the 3-level 5-dimension EuroQoL, the Medical Outcomes Study 36-Item Short-Form version 2 (SF-36v2), and the Work Productivity and Activity Impairment (WPAI) questionnaires.

Among the total cohort, 640 patients (43.4%) were included in the analysis who were receiving TNFis for 3 months and had completed the SF-36v2 bodily pain and vitality domains of the questionnaire. Overall, 37.7% and 45.6% of patients reported severe pain and fatigue, respectively. A greater percentage of patients who reported severe vs low or no pain and fatigue were considered to have severe and unstable/deteriorating disease by their physicians, respectively. In addition, a higher percentage of patients who reported severe vs low or no pain and fatigue had current flares. A total of 83.3% and 88.0% of patients who reported severe pain and fatigue, respectively, were considered to have stable/improving disease by their physicians; however, physicians reported that 39.8% and 45.5% of patients with severe pain and fatigue were considered to be in remission, which indicated a discordance between patient and physician assessment of pain and fatigue.

Scores across HRQoL and WPAI were significantly different across the pain and fatigue severity cohorts (P <.0001). Both HRQoL and WPAI measures were worse in patients with moderate to severe vs low pain and/or fatigue, indicating an association with greater work impairment.

Based on these findings, the investigators indicated that despite treatment with TNFis, patients with PsA experienced substantial pain and/or fatigue, which was associated with decreased HRQoL, physical function, and work productivity.

Study limitations included the potential subjectivity of physicians ratings, the variability of reporting across regions, and the inclusion of pain and fatigue data only from patients receiving TNFis.

Researchers concluded, The high burden that severe pain and/or fatigue, in spite of TNFi treatment, place on patients in terms of limited function, diminished HRQoL and reduced ability to contribute to society as part of the workforce indicate that these are areas of significant unmet need in the treatment and management of PsA.

Conaghan PG, Alten R, Deodhar A, et al. Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study [published online July 1, 2020]. RMD Open. doi:10.1136/rmdopen-2020-001240

See original here:
Pain and Fatigue in PsA Linked to Reduced Quality of Life, Physical Function, and Work Productivity - Rheumatology Advisor

DE PERE, Wis. (WFRV) July is Juvenile Arthritis Awareness Month. The disease 300,000 kids have been diagnosed with nationwide.

A De Pere 12-year-old is speaking out about her experience with the autoimmune disease after being diagnosed at just four years old.

Lily Laurent says arthritis mostly impacts her knees and legs. She and her mother, Anne, spoke with WFRV Local 5 about how it has impacted their family and how much of a difference finding a community has made.

When we were first diagnosed, we didnt know another family I mean, I didnt even know kids could get arthritis and we ended up at the rheumatologist, Anne tells WFRV Local 5. It can be scary, and you can feel alone. And there are groups, in Green Bay and the Fox Valley and in Wisconsin, where weve met other families and shes met other kids.

There is no known cure for the disease, but Lily is doing well and heading toward remission.

Her doctor says that patients should watch for the symptoms of juvenile arthritis, such as unusual amounts of aches and pains.

If your child has redness and swelling and especially a lot of stiffness in the morning where theyre walking like an old man or old woman, limping, I mean these are the signs that should, you know, at least, first start with your pediatrician, Dr. Paul Tuttle, a rheumatologist with Orthopedic & Sports Medicine in Green Bay, tells WFRV Local 5.

Lily created a video about her journey with arthritis.

Continued here:
De Pere girl discusses experience with juvenile arthritis - WeAreGreenBay.com

A new intelligence report Rheumatoid Arthritis Treatment Market has been recently Added into Global Market Research collection of top-line market research reports. Global Rheumatoid Arthritis Treatment Market report is a meticulous comprehensive analysis of this market that provides access to direct first-hand insights on the growth trail of market in near term and long term. On the basis of factual advice sourced from authentic industry pros and extensive main industry research, the report provides insights about the historical growth pattern of Rheumatoid Arthritis Treatment Market and current market situation. It then provides short- and long-term market development projections.

Projections are purely based on the detailed analysis of key Market dynamics that are expected to influence Rheumatoid Arthritis Treatment Market performance and their intensity of impacting market growth within the span of assessment period.

Request Sample Report @ https://www.futuremarketinsights.co/reports/sample/REP-GB-3119

In addition to evaluation of dynamics, the report provides In-depth examination of key business trends that are expected to act more prominently in global Rheumatoid Arthritis Treatment Market. The study also provides valued information about the present and upcoming growth opportunities in Rheumatoid Arthritis Treatment Market the important players and new market entrants can capitalize on.

Competitive companies And manufacturers in global market

key players and products offered

Potential and niche segments, geographical regions exhibiting promising growth

A neutral perspective on market performance

Must-have information for market players to sustain and enhance their market footprint

NOTE All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of Future Market Insights.

Request Methodology On This Report @ https://www.futuremarketinsights.co/askus/REP-GB-3119

Opportunity assessment Provided in the Rheumatoid Arthritis Treatment Market report Is important concerning understanding the profitable regions of investment, which are the technical insights for major market players, suppliers, vendors, and other stakeholders in Rheumatoid Arthritis Treatment Market.

In-depth global Rheumatoid Arthritis Treatment Market taxonomy presented in this Report offers detailed insights about each of the market sections and their sub-segments, which are categorized based on par various parameters. An exhaustive regional evaluation of global Rheumatoid Arthritis Treatment Market divides international market landscape into essential geographies.

Regional outlook and country-wise evaluation of Rheumatoid Arthritis Treatment Market Allows for the evaluation of multi-faceted performance of market in all the crucial markets. This advice plans to provide a wider scope of report to readers and identify the most relevant profitable areas in global market place.

Key Regions and Countries Covered in Global Rheumatoid Arthritis Treatment Market Report-

Taxonomy and geographical analysis of the international Rheumatoid Arthritis Treatment Market empowers readers to spot profits in present chances and catch upcoming growth opportunities even until they approach the market location. The analysis given in report is only intended to unroll the economic, societal, regulatory and political scenarios of the marketplace specific to each area and country, which might help prospective market entrants in Rheumatoid Arthritis Treatment Market landscape to comprehend the nitty-gritty of target market regions and invent their strategies accordingly.

We offer tailor-made solutions to fit your requirements, request[emailprotected] https://www.futuremarketinsights.co/customization-available/REP-GB-3119

Major TOC Covered In this Report are:

Here is the original post:
Advancements in Technology to Aid the Growth of the Rheumatoid Arthritis Treatment Market Over the Forecast Period 2017-2027 - Jewish Life News

Here are the top stories recently covered by DocWire News in the rheumatology section. In this edition, read about sarilumab in COVID-19, glucocorticoidsin rheumatoid arthritis (RA), body weight and the risk of tumor necrosis factor inhibitor discontinuation in RA, and healthcare utilization predictors of inflammatory arthritis.

Rheumatoid arthritis (RA) drugsarilumab was not an effective treatment for severely ill COVID-19 patients, according to the results of a phase 3 trial. The U.S.-based study was a phase 3 trial comparing 400 mg sarilumab plus best supportive care versus best supportive care alone for COVID-19 patients requiring mechanical ventilation.According to Regeneron, 80% of Kevzara patients and 77% of best supportive care patients in the primary analysis group sustained adverse events (AEs). Serious AEs documented in at least 3% of patients and were more common in the sarilumab group than the best supportive care group included multiorgan dysfunction syndrome (6% vs. 5%) and hypotension (4% vs. 3%). This study has been stopped in the 400 mg group as well as in a higher-dose cohort.

Astudy compared the effect of low-dose glucocorticoids plus methotrexate and hydroxychloroquine versus placebo plus methotrexate andhydroxychloroquineon symptoms, signs, and inflammation in early RA. After one month of treatment, American College of Rheumatology 20 (ACR20) response was achieved by 55% of the glucocorticoids group and 20% of the placebo group. At month three, 85.0% of the glucocorticoids group and 47.5% of the placebo group achieved ACR20 response; at months six and 12, the rates were 87.5% versus 60.0%, respectively, and 90.0% versus 72.5%, respectively (P<0.05 for all). During the first half of the treatment period, the trial group had significantly lower disease activity score (DAS) 28- erythrocyte sedimentation rate (ESR) scores than the control group. Inflammation, quality of life, and radiological symptoms improved significantly in the glucocorticoids group. Bone erosion did not change in the trial group and worsened in the control group. The correlation coefficient between disease duration and DAS28-ESR score was 0.496 for month one, 0.464 for month three, 0.509 for month six, and 0.550 for month 12. Rates of adverse events did not largely differ between the groups.

RA patients with either a low orhigh body mass index(BMI) are more likely than normal weight RA patients to discontinue treatment withtumor necrosis factor inhibitors (TNFis), according to a study. Final analysis included 5,230 RA patients. TNFi survival, when compared to that of normal weight patients, was significantly shorter among patients inobesity class II(hazard ratio [HR]=1.28; 95% confidence interval [CI], 1.06 to 1.54), obesity class III (HR=1.67; 95% CI, 1.29 to 2.18), and the underweight group (HR=1.30; 95% CI, 1.07 to 1.58). Among the underweight group, the most significant effect was observed for patients on infliximab (HR=1.82; 95% CI, 1.20 to 2.76). In overweight patients, the most significant effect was noticed for patients taking infliximab (obesity class II: HR=1.49; 95% CI, 0.98 to 2.26; obesity class III: HR=1.46; 95% CI, 0.79 to 2.71) and etanercept (obesity class II: HR=1.27; 95% CI, 0.98 to 1.65; obesity class III: HR=1.79; 95% CI, 1.25 to 2.55).

Patients who eventually go on to be diagnosed withinflammatory arthritis (IA)often present withmusculoskeletal symptoms, infections, and comorbidity leading up to their diagnosis, according to a study. During the 1.5-year period before their diagnosis, IA patients were significantly more likely than controls to have health visits for musculoskeletal symptomsprimarily for shoulders, wrists, fingers, and kneesand carpal tunnel syndrome. The odds ratio (OR) was highest at six months prediagnosis (3.2; 95% confidence interval [CI], 2.8 to 3.5), followed by 12 months (OR=2.8; 95% CI, 2.5 to 3.1) and 18 months (OR=2.5; 95% CI, 2.2 to 2.8).

See the original post:
Rheum Round-up: Sarilumab Flops in COVID-19, RA TNFi Termination and Body Weight, and more - DocWire News

A drug used to treat brain haemorrhage and arthritis could help patients battling COVID-19.

A coronavirus patient at Wythenshawe Hospital has become the first to take part in the trial a drug called Anakinra.

Anakinra is an immunosuppressive drug mainly used to treat rheumatoid arthritis but also certain types of brain haemorrhage.

Researchers say the drug can combat severe infections and multiple organ failure triggered by an overreactive response by the bodys immune system.

This immune response can result in death and can occur in critically-ill COVID-19 patients.

The new trial is comparing the drugs effectiveness in treating critically ill patients when administered either by injection under the skin or into the vein.

Dr Tim Felton, a consultant in Intensive Care and Respiratory Medicine at Manchester University NHS Foundation Trust (MFT), is leading the study.

He said: "Anakinra is highly effective in treating overreactive immune response and severe infections.

"Because of this it could prove effective in treating COVID-19 patients, and several global trials are now underway to investigate this.

"The drug is typically administered as an injection either into the vein or under the skin.

"We think injection under the skin is a more efficient way of delivering the drug and thats why with SCIL-1Ra we want to compare the two methods.

"We hope to show one method is more effective than the other and deliver better outcomes for patients."

Dr Bannard-Smith, an ICU consultant and lead Covid researcher at the MRI, added: Were incredibly grateful to our patient and their family for participating in the trial, and our fantastic team at Wythenshawe Hospital for their excellent patient care and hard work in coordinating this study.

"MFT is at the forefront in delivering cutting-edge research to fight COVID-19. Anakinra is currently being trialled as a potential COVID-19 treatment by several major UK and international studies, and we hope this one will make a vital contribution to wider efforts to understand the drugs effectiveness."

The study, called SCIL-1Ra, aims to recruit 40 adult patients in intensive care with confirmed or clinically suspected COVID-19.

It's one of many COVID-19 treatment trials underway at hospitals across Greater Manchester.

View original post here:
Drug used to treat brain haemorrhage and arthritis is being tested on Covid patients at Wythenshawe Hospital - Manchester Evening News

The research report on theglobal Rheumatoid Arthritis Treatment Market is a comprehensive guide for new market entrants. The report provides the market history of each product retailed by the company. It likewise gives a background marked by item types, innovation and volume during the figure time frame. The growth rate, challenges and obstacles are also explained in the Global Rheumatoid Arthritis Treatment study report. The report features the pace of improvement of the methodologies, items and advances utilized in the creation, assembling and promoting of the item.

The following Top manufacturers are evaluated in this report: Pfizer, Inc., Johnson & Johnson, Abbvie, Inc., F. Hoffmann-La Roche AG, Merck & Co., Inc., and Amgen, Inc.,

* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

To Get More Insightful information | Request a sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/166

This report sample includes

Brief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The market report contains the following chapters:

Chapter 1: The Global Market Research Report Rheumatoid Arthritis Treatment Help Understand Crucial Information About The Given Market. Chapter 2: The report provides a detailed study on each actor having a major impact on the global market Rheumatoid Arthritis Treatment, such as company profiles, the latest technological advances of market players and the product profile of the player currently available in the market, as well as the regions in which they operate mainly. Chapter 3: It helps to understand the key product segments and their future on the global market Rheumatoid Arthritis Treatment. It provides strategic solutions and recommendations in key business sectors based on market estimates. Chapter 4: The report also presents an eight-year forecast survey based on expected market growth.

The Global Rheumatoid Arthritis Treatment Market report analyzes the production of goods, supply, sales and the current state of the market in detail. In addition, the report examines the market share of production and sales of products, as well as capacity, production capacity, sales trends, cost analysis and revenue generation. Several other factors such as import/export status, industrial statistics, supply and demand ratio, gross margin and the structure of the industrial chain were also studied in the Global Rheumatoid Arthritis Treatment Reports.

Rheumatoid Arthritis Treatment Market Regional Analysis:

Geographically, the Rheumatoid Arthritis Treatment market is segmented across the following regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.

Key Coverage of Report:

Key insights of the report:

The report conveys key measurements on the current market status of the Rheumatoid Arthritis Treatment makers and is a dependable wellspring of direction and course for the organizations and people intrigued by the business in the industry. The report delivers an overview of the industry, including the basic definition, applications, the latest manufacturing technology, and others. The report comprises of the company profile, product specifications, production capacity, production value, and market shares for the key competitors. The market is additionally partitioned by an organization, by nation, and by application/type for the serious scene investigation. The report forecasts market development trends of the Rheumatoid Arthritis Treatment industry from 2016 to 2027.Analysis of the upstream raw materials, downstream demand and current market dynamics is also carried out efficiently. The report states the important growth prospects and proposals for a new project in the global Rheumatoid Arthritis Treatment Industry.

Note: *The Download PDF brochure only consists of Table of Content, Research Framework, and Research Methodology.

To Get PDF Brochure Click Here @ https://www.coherentmarketinsights.com/insight/request-pdf/166

STAY HOME STAY SAFE

Read this article:
Rheumatoid Arthritis Treatment Market trends, drivers, restraints, and opportunities 2020-2026 - Daily Research Chronicles

The stereotypic image of a person with gout is the overweight middle-aged male who indulges in rich food and consumes too much alcohol. Although this may certainly be an example of someone with gout, this common and complex form of arthritis can affect anyone.

Gout is, in fact, an inherited metabolic disease related to insulin resistance. Gout typically manifests as acute, very painful arthritis of the big toe but in reality, can affect any of the major joints in the body. Although the last thing you want to experience is painful arthritis, gout has other associations and as with all other medical conditions, the best treatment of gout is prevention.

The basic metabolic abnormality is an elevated uric acid a waste product created during the normal breakdown of purines (a type of chemical found in foods and drinks). The crystals of uric acid precipitate in the joint leading to the painful arthritis. But these crystals of uric acid can also affect the kidney leading to varying degrees of kidney impairment and hypertension (high blood pressure).

There are very effective treatments to settle down an acute episode, but there is also a drug that has been available for many years, which in most cases is very safe: allopurinol (sold under the brand names Allohexal, Allosig, Progout and Zyloprim). Taking allopurinol once the episode has settled in increasing doses to a maintenance of 300mg daily should prevent gout with minimal, if any, side effects. This will not only prevent further episodes of gout but will also protect the kidney from damage and help reduce blood pressure.

Interestingly, a recent large study published in the Journal of Hypertension of just under 24,000 people with hypertension showed the commonly prescribed blood pressure pill amlodipine when compared with diuretic or another commonly prescribed group of blood pressure drugs, ACE inhibitors, lowers the risk for gout by around 35 per cent.

So if you have unfortunately experienced gout in your life and also have hypertension, its worth discussing with your doctor the preventative management for gout, but also taking the appropriate therapy for your blood pressure.

IMPORTANT LEGAL INFO This article is of a general nature and FYI only, because it doesnt take into account your personal health requirements or existing medical conditions. That means its not personalised health advice and shouldnt be relied upon as if it is. Before making a health-related decision, you should work out if the info is appropriate for your situation and get professional medical advice.

Follow this link:
The best way to treat a gout attack - Starts at 60

TheGlobal Psoriatic Arthritis Therapeutics Market Outlook and Forecast 2020-2025A fundamental outline of thePsoriatic Arthritis Therapeutics Marketniche is presented by the Psoriatic Arthritis Therapeutics Market report that entails definitions, classifications, applications together with industry chain framework. ThePsoriatic Arthritis Therapeutics Marketreport provides a far-reaching evaluation of necessary market dynamics and the latest trends. It also highlights the regional market, the prominent market players, as well as several market segments [Product, Applications, End-Users, and Major Regions], and sub-segments with a wide-ranging consideration of numerous divisions with their applications.

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Request Free Sample Report of Psoriatic Arthritis Therapeutics Market Report @https://www.zionmarketresearch.com/sample/psoriatic-arthritis-therapeutics-market

Some of the Major Market Players Are:

AbbVie, Amgen, Celgene Corporation, Janssen Biotech, UCB, Pfizer, Biogen, Novartis AG, Eli Lilly and Company

Further, the report acknowledges that in these growing and promptly enhancing market circumstances, the most recent advertising and marketing details are very important to determine the performance in the forecast period and make essential choices for profitability and growth of the Psoriatic Arthritis Therapeutics Market. In addition, the report encompasses an array of factors that impact the growth of the Psoriatic Arthritis Therapeutics Market in the forecast period. Further, this specific analysis also determines the impact on the individual segments of the market.

Furthermore, the study assessed major market elements, covering the cost, capacity utilization rate, growth rate, capacity, production, gross, usage, revenue, export, supply, price, market share, gross margin, import, and demand. In addition, the study offers a thorough segmentation of the global Psoriatic Arthritis Therapeutics Market on the basis of geography [ Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] , technology, end-users, applications, and region.

Download Free PDF Report Brochure@https://www.zionmarketresearch.com/requestbrochure/psoriatic-arthritis-therapeutics-market

Note In order to provide more accurate market forecast, all our reports will be updated before delivery by considering the impact of COVID-19.

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The Psoriatic Arthritis Therapeutics Market report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments.

The Psoriatic Arthritis Therapeutics Market report is an appropriate compilation of all necessary data for the residential, industrial. & commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projected as well as the prevailing trends in the Psoriatic Arthritis Therapeutics Market. Apart from this, the report also provides insightful particulars of the existing policies, laws, together with guidelines.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/psoriatic-arthritis-therapeutics-market

Promising Regions & Countries Mentioned In The Psoriatic Arthritis Therapeutics Market Report:

Chapters Covered in Research Report are :

Chapter 1,2 :The goal of global Psoriatic Arthritis Therapeutics Market covering the market introduction, product image, market summary and development scope.

Chapter 3, 4 :Global Market Competitions by Manufacturers, Sales Volume and Market Profit.

Chapter 5,6,7:Global Supply (Production), Consumption, Export, Import by Regions like United States, Asia-Pacific, China, India, Japan. Conducts the region-wise study of the market based on the sales ratio in each region, and market share from 2015 to 2024

Chapter 8,9,10:Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributors/Traders

Chapter 11,12 :Market information and study conclusions, appendix and data sources.

The market report also identifies further useful and usable information about the industry mainly includes Psoriatic Arthritis Therapeutics Market development trend analysis, investment return and feasibility analysis. Further, SWOT analysis is deployed in the report to analyze the key global market players growth in the Psoriatic Arthritis Therapeutics Market industry

Request the coronavirus impact analysis across industries and market

Request impact analysis on this market @https://www.zionmarketresearch.com/custom/4271?covid19=true

Purposes Behind Buying Psoriatic Arthritis Therapeutics Market Report:-

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Continue reading here:
Global Psoriatic Arthritis Therapeutics Market Outlook and Forecast 2020-2025 - 3rd Watch News

Arthritis is the most common form of peripheral joint arthritis and cause of disability in the UK. It affects mostly the knee, hip, hand, and feet joints. It is a chronic musculoskeletal disorder characterised by involvement of all joint structures including the synovial membrane, cartilage and bone. Those suffering with the condition experience joint pain, reduced participation in daily activities and poor quality of life. Fortunately, including more of these delicious fruits could help.

Tart cherries get their rich red colour and many of their powerful anti-inflammatory and antioxidant benefits from the flavonoid anthocyanin, said the Arthritis Foundation.

The health site added: These properties make tart cherries a popular research subject, and some investigators compare the effects to nonsteroidal anti-inflammatory drugs.

One study found that drinking tart cherry juice two times per day for three weeks resulted in considerable reductions in vital inflammation markers, especially for participants who had the highest inflammation levels at the start of the study.

READ MORE:Arthritis pain - breakfast swap that could lower your risk of symptoms

Watermelons are high in the carotenoid beta-cryptoxanthin, which helps to reduce the risk of rheumatoid arthritis, according to studies which followed peoples dietary habits over time, said Arthritis Foundation.

Nutritionist Victoria Jarzabkowski added: The lycopene in watermelon makes it an anti-inflammatory fruit.

Lycopene is also known to help protect certain cancers and lower heart attack risk.

DON'T MISSArthritis: A vegetable to ease pain[DIET]Arthritis treatment: Take this herbal extract to reduce pain[REMEDY]Arthritis pain - the best oil to use while cooking your dinner[DIET]

Unlike most fruits, avocados are a good source of vitamin E, a micronutrient with anti-inflammatory effects said Arthritis Foundation.

The site added: Diets high in these compounds are linked to decreased risk of the joint damage seen in early osteoarthritis.

Studies also show eating avocados daily increases good HDL cholesterol and lowers bad LDL cholesterol.

When it comes to foods to avoid, processed foods are up there.

Foods including baked goods, pre-packaged meals and snacks.

These items contain trans-fat to help preserve them, and trans fats trigger systemic inflammation.

Its imperative to carefully read food labels as many contain hydrogenated oils which should be avoided.

There is no cure for arthritis, but there are many treatments that can help slow it down, said the NHS.

It added: Osteoarthritis treatments include lifestyle changes, medicines and surgery.

Treatment for rheumatoid arthritis aims to slow the conditions progress and minimise joint inflammation. This helps prevent joint damage.

Treatments include medication, physiotherapy and surgery.

See more here:
Arthritis: Three of the best fruits to incorporate into your diet to reduce symptoms - Express

Magnetic resonance imaging (MRI)-detected erosions of the hand and feet were not predictive of rheumatoid arthritis (RA) in patients with arthralgia, according to study data published in the Scandinavian Journal of Rheumatology. Instead, MRI-detected subclinical inflammation was the strongest correlate of later disease progression in patients with clinically suspect arthralgia.

The study cohort comprised patients with recent-onset (<1 year) arthralgia in the small joints who received care at a rheumatology clinic in Leiden, the Netherlands. Patients were enrolled between April 2012 and October 2018. Individuals were excluded if clinical arthritis was detected at baseline or if another etiology for joint arthralgia was present. At baseline, patients underwent a physical examination, blood draw, and high-contrast MRI of the hands and feet. Erosions were scored using the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system. Follow-up visits were conducted at 4, 12, and 24 months. Patients who initiated treatment with disease-modifying antirheumatic drugs during follow-up were excluded from analyses.

The primary outcome was diagnosis of inflammatory arthritis, determined by the treating rheumatologist. Multivariable logistic regression was performed to assess the relationship between MRI-detected lesions and later diagnosis of arthritis. Analyses were stratified by anticitrullinated protein/peptide antibody (ACPA) positivity and adjusted for patient age and subclinical inflammation levels.

The study cohort comprised 490 patients, of whom 83 developed inflammatory arthritis during follow-up. Median follow-up time to inflammatory disease diagnosis was 14 weeks (interquartile range, 3-23 weeks). Median follow-up duration in patients who did not progress to arthritis was 103 weeks (interquartile range, 51-113 weeks). Median total erosion score was greater in patients who progressed to arthritis compared with patients who did not.

The presence of MRI-detected erosions was not significantly associated with arthritis development in either the univariate model (hazard ratio, 1.40; 95% CI, 0.86-2.28) or the model adjusted for age and subclinical inflammation (hazard ratio, 0.97; 95% CI, 0.59-1.59). Analyses were then restricted to RA-specific erosions: grade 2 erosions, erosions of the fifth metatarsophalangeal joints (MTP5), and erosions in MTP1 in patients aged <40 years. None of these erosion types were predictive of later progression to inflammatory disease.

In analyses stratified by ACPA status, these trends persisted: MRI-detected erosions did not predict disease progression in either ACPA subset. The researchers instead found subclinical inflammation level to be the strongest predictor of later disease progression. Area under the receiver operating characteristic curve (AUC) was 0.73 for subclinical inflammation vs 0.54 for MRI erosion. When MRI-detected erosion was added to the model, the AUC remained at 0.73, suggesting that prognostic accuracy was not improved by erosion assessment.

Results from this longitudinal study indicated that MRI-detected erosions of the hands and feet are not predictive of later arthritis development in patients with clinically suspect arthralgia. This implies that evaluating MRI erosions of [patients with clinically suspect arthralgia] is superfluous if MRI-detected subclinical inflammation is assessed, the investigators wrote.

Reference

Wouters F, Matthijssen XME, Boeters DM, et al. Do magnetic resonance imaging-detected erosions predict progression to rheumatoid arthritis in patients presenting with clinically suspect arthralgia? A longitudinal study [published online June 2, 2020]. Scand J Rheumatol. doi:10.1080/03009742.2020.1737221

View post:
MRI-Detected Erosions of the Small Joints Not Predictive of Later Rheumatoid Arthritis - Rheumatology Advisor

Arthritis affects around 10 million people in the UK, according to the charity Versus Arthritis. Don't wait until symptoms become unbearable, notice these common signs to begin early treatment.

Charity Arthritis Foundation point out the four most common warning signs of the condition.

1. Pain

First, there will be a sensation of pain. This can come and go whether resting or moving or it may be persistent.

The pain can be found in one specific area of the body or it could occur in different parts.

2. Swelling

There are various types of arthritis (which will be noted later), but a certain type of arthritis can cause swelling.

The skin over the affected joint can become red and swollen, feeling warm to the touch.

Swelling can last for a couple of days, which requires medical attention. This is also true if swelling occurs more than three times in a month.

3. Stiffness

Stiffness tends to be apparent when waking up first thing in the morning especially if it lasts longer than an hour after rising.

READ MORE:Vitamin deficiency warning: New study suggest vitamin deficiencies impair brain function'

It also reveals itself after sitting at a desk for a long time, or you may feel stiff after taking a long car journey.

4. Difficulty moving a joint

If you're finding it difficult or painful to get up from a chair, it's likely you have arthritis.

Types of arthritis

There are lots of different types of arthritis far too many to delve into in one article.

The three most common types of arthritis are: osteoarthritis, gout and rheumatoid arthritis.

DON'T MISS

Osteoarthritis

Versus Arthritis explained that osteoarthritis begins with the roughening of cartilage.

Cartilage is responsible for cushioning the ends of bones, however, once it begins to roughen, tiny bits of extra bones (osteophytes) can extend from bones in the joint.

Moreover, there can be an increase in the amount of thick fluid inside the joint.

And the joint capsule can stretch, resulting in the joint losing its shape.

Gout

Gout is a type of inflammatory arthritis that can cause painful swelling in the joints (spoken about earlier).

The most common joint affected is the big toe, but any joint suffering from gout can become red and hot.

The skin over the inflamed joint can look shiny and can peel. The condition is caused by too much urate (uric acid) in the body.

Although a small amount of urate is normal, excess urate can develop based on genetics, or what you eat or drink.

Rheumatoid arthritis

Rheumatoid arthritis is another type of inflammatory arthritis, when the body's immune system mistakenly attacks the body's joints.

The autoimmune disorder collects extra blood and fluid to the affected joint(s) which can cause a number of problems.

For example, it can make moving the joints difficult and painful, as the fluid can irritate nerve endings.

Moreover, the extra fluid can stretch the joint capsule, dislodging the joint from its original position.

Read the rest here:
Arthritis symptoms: The four most common signs you have the health condition - Express

Eating dark, leafy vegetables along with fish and fruits similar to the Mediterranean diet is one of the best ways to eat to help reduce symptoms of arthritis.

Dr Lex Mauger, co-author of the study and Director for BSc Sports Science at the University of Kent, said: The Mediterranean diet has previously been associated with a number of health benefits, but the exciting finding with this study is that specific guidance on adhering to this type of diet can change eating behaviour and result in a number of beneficial physiological changes, relevant to osteoarthritis, in a relatively short period of time.

As osteoarthritis is a chronic disease, treatment is primarily about managing the symptoms, and this study shows that eating healthily may help form part of that treatment strategy.

Benefits from the intervention in this study were evident after only four months, so it is possible that an even greater benefit could be seen in people who make longer-term improvements to their normal diet.

Read the original:
Arthritis: Eating more of this vegetable will help reduce pain felt in the joints - Express